drugset / Trial / NCT01141881

Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema

NCT01141881

Single-blindTreatment

Summary

Purpose: to evaluate the effect of intravitreal injection of tissue plasminogen activator(tPA) in treatment of refractory diabetic macular edema(DME).

Timeline

Start
2009-05
Primary completion
2010-01
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 25 ug Intravitreal
Background Bevacizumab Monoclonal antibody 1.25 mg